Premium
Cytotoxicity of TRAIL/Anticancer Drug Combinations in Human Normal Cells
Author(s) -
MEURETTE OLIVIER,
FONTAINE ANNE,
REBILLARD AMELIE,
LE MOIGNE GWENAELLE,
LAMY THIERRY,
LAGADICGOSSMANN DOMINIQUE,
DIMANCHEBOITREL MARIETHERESE
Publication year - 2006
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1378.023
Subject(s) - cytotoxicity , cisplatin , apoptosis , cancer cell , tumor necrosis factor alpha , cancer , cancer research , chemotherapy , chemistry , cytotoxic t cell , pharmacology , medicine , immunology , in vitro , biochemistry
TRAIL (TNF‐α‐Related Apoptosis‐Inducing Ligand) is a promising anticancer agent. In fact, it induces apoptosis in cancer cells and not in most normal cells. Nevertheless, certain cancer cells are resistant to TRAIL‐induced apoptosis and this could limit TRAIL's efficiency in cancer therapy. To overcome TRAIL resistance, a combination of TRAIL with chemotherapy could be used in cancer treatment. However, sensitivity of human normal cells to such combinations is not well known. We showed in this study that TRAIL/cisplatin, in contrast to TRAIL/5‐fluorouracil, was toxic toward human primary hepatocytes and resting lymphocytes. Furthermore, both combinations are toxic toward PHA‐IL2‐activated lymphocytes. In contrast, freshly isolated neutrophils are resistant to TRAIL in combination or not with anticancer drugs.